<DOC>
	<DOCNO>NCT01489774</DOCNO>
	<brief_summary>Study objectives - To evaluate safety , tolerability , pharmacokinetics escalate single oral dos CJ-12406 healthy male subject . - To evaluate pharmacodynamics CJ-12406 multiple oral administration healthy male subject . - To evaluate effect food pharmacokinetic single oral dose CJ-12406 healthy male subject .</brief_summary>
	<brief_title>Phase I Study Investigate Safety , Tolerability , Pharmacokinetics/Pharmacodynamics CJ-12406 Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<criteria>1 . Male volunteer age 20 45 year old 2 . Subjects history significant chronic disease 3 . The weight range exceed ±20 % ideal weight . Ideal weight = [ height 100 ] *0.9 4 . Judged good health basis vital sign , ECG , physical exam routine laboratory data 5 . Available entire study period 6 . Willing adhere protocol requirement sign inform consent form 7 . Multiple escalation study ; H. pylorus positive , determined urea breath test 1 . History clinically significant allergy include drug allergy 2 . History clinically significant hepatic , renal , gastrointestinal , pulmonary , , musculoskeletal , endocrine , psychiatric , hematologic , oncologic , neurologic cardiovascular disease 3 . Symptom acute illness within 4 week prior drug administration 4 . History surgery except gastrointestinal disease might significantly change absorption medicine 5 . Treatments symptoms symptomatic GERD , gastric ulcer , duodenal ulcer , functional dyspepsia , irritable bowel syndrome within 3 month prior drug administration 6 . Clinical laboratory test value outside accept normal range AST ALT &gt; 1.25 time normal range Creatinine clearance &lt; 80 mL/min 12lead ECG ; PR ≥ 210 msec , QRS ≥ 120 msec , QT ≥ 500 msec , QTcF ≥ 450 msec 7 . Clinically significant vital sign Hypotension ( SBP ≤ 89 mmHg ) Hypertension ( SBP ≥ 141 mmHg DBP ≥ 91 mmHg ) Tachycardia ( ≥ 101 beats/min ) 8 . History drug alcohol abuse ( alcohol &gt; 30 g/day ) 9 . Subjects ever smoke within 3 month prior drug administration 10 . Positive urine screen drug cotinine 11 . Use medication , include herbal product , within 2 week dose 12 . Special diet know interfere absorption , distribution , metabolism excretion drug ( especially , consumption grapefruit juice ) within 7 day prior drug administration 13 . Donated blood within 60 day prior dose 14 . Participated previous clinical trial within 90 day prior dose 15 . Subjects consider unsuitable base medical judgement investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>